Our research center is dedicated to the research, development and progress of new therapies for a number of different disorders that will improve the quality of life for patients. We are continually enrolling patients of all ages in research studies. We may have a study that is right for you! Please look below at our currently enrolling studies. If interested, please call us at 949-347-8700 x1800.
Currently Enrolling Studies
Food Allergy
Alladapt Harmony Study: A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults 4 - 55 years of age to ENROLLING
Chronic Spontaneous Urticara: Adults
AstraZeneca D3259C00001: A Phase 2b Multinational, Randomized, Double-Blind, Parallel-Group, 24-week Placebo-controlled Study with 28-week Extention to Investigtae the Use of Benralizumab in Patients with Chronic Spontaneous Urticaria Who are Symptomatic Despite the Use of Antihistamines (ARROYO)
Chronic Spontaneous Urticara: Adults
Amgen 20190194: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
Chronic Cough
Bellus BUS-P2-02 A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallet-Arm Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
No Current Active Studies
No Current Active Studies
No Current Active Studies
No Current Active Studies
Active Non-Enrolling Studies
No Current Active Studies
Active Non-Enrolling
Long-Term Assessment of Safety and Therapeutic Benefit of Viaskin Peanut Epicutaneous Treatment in Peanut-Allergic Children: A 6-month Randomized, Double-Blind, Placebo-Controlled Phase III Study Followed by An Open Label Active Treatment (REALISE Study)
Active Non-Enrolling
Efficacy and safety of AR101
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut allergic children and adults.
Completed Studies
Enrolling
A Randomized, double-blind, placebo-controlled, multi-center study of the Efficacy and Safety of STG320 sublingual tablet of house dust mite (HDM) allergen extracts in adults and adolescents with HDM-associated allergic rhinitis
Completed
Genentech GS39684: A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOTAND DOSE-RANGING STUDY OF GDC-0853 IN PATIENTS WITH REFRACTORY CHRONIC SPONTANEOUS URTICARIA (CSU)
Completed
Novartis CLOU064A2201: A multicenter, randomized, double-blind, placebo-controlled Phase 2b dose- finding study to investigate the efficacy, safety and tolerability of LOUD064 in adult chronic spontaneous urticarial patients inadequately controlled by H1-antihistamines
Completed
Cipla U-FS-MU-AS3120: A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 µg inhalation powder (Cipla Ltd., India) with Advair®Diskus 100/50 µg (GlaxoSmithKline, USA) in Asthma Patients
Completed
Gossamer GB001-2001: A Phase 2b, randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the efficacy and safety of GB001 as maintenance therapy in adult subjects with moderate to severe asthma
Completed
Amphastar API-A008-BE-PD: A Randomized, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Crossover PD Study
Completed
TEVA TPI-18-03: A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg in Adult Subjects with Asthma
Completed
Aimmune ARC007 Real World AR101 Market Supporting Experience Study in Peanut Allergic Children Ages 4 to 17 years (RAMSES)
Completed
Regeneron R668-ALG-16114: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study In Pediatric Subjects With Peanut Allergy To Evaluate The Efficacy And Safety Of Dupilumab As Adjunct To AR101 (Peanut Oral Immunotherapy).
Completed
AbbVie M16-045: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Completed
Incyte INCB 18424-304: A Phase 3, Double-Blind, Randomized, 8-week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescent and Adults with Atopic Dermatitis
Completed
Pfizer B7451029: A Phase 3 Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Center Study Investigating The Efficacy and Safety of PF-04965842 and Dupilumab in Comparison with Placebo in Adult Subjects on Background Topical Therapy, With Moderate to Severe Atopic Dermatitis.
Completed
Regeneron R668-AD-1652: A Randomized, Double-Blind, Placebo-Controlled Study To Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly with Topical Corticosteroids in Patients ≥ 6 Years To <12 Years of Age with Severe Atopic Dermatitis
Completed
Pfizer B7451036: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating The Efficacy and Safety of PF-04965842 Co-Administered With Background Medicated Topical Therapy in Adolescent Participants 12 to < 18 years of age with Moderate to Severe Atopic Dermatitis.
Completed
AstraZeneca D3250C00045 A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg SC in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment
Completed
Multidose Study Comparing the Therapeutice Equivalence of a 3M inhaler and a Symbicort Reference Inhaler, Each Delivering Budesonide/Formoterol Fumarate (80 mcg/4.5 mcg).
Completed
A Study of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy, safety and tolerability of lebrikizumab in adolescent patients with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid therapy and at least one second controller medication. Patients will be randomized 1:1:1 to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. The anticipated time on study treatment up to 104 weeks. After study treatment, all patients will complete a 20 week safety follow-up.
12 Years to 17 Years
Both Male & Female
Completed
A randomized, double-blind, placebo-controlled study of the efficacy, safety and tolerability of serlopitant for the treatment of refractory chronic cough
Completed
Attenua ATA101-PN-001: A Dose Escalation Study to Assess the Efficacy and Safety of ATA-101 in Subjects with Refractory Chronic Cough
Allergic Rhinitis for Children
Glenmark: A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared with Placebo Nasal Spray in Pediatric Subjects (aged 6 to under 12 years) With Seasonal Allergic Rhinitis (SAR)
Completed
Evaluation of Dupilumab in Patients With Persistent Asthma
Primary Objective: To evaluate the efficacy of dupilumab in patients with persistent asthma.
Secondary Objectives: To evaluate the safety and tolerability of dupilumab. To evaluate the effect of dupilumab in improving patient-reported outcomes including health-related quality of life. To evaluate dupilumab systemic exposure and incidence of antidrug antibodies.
12 years and older
Both Male & Female
Completed
A Randomized, Double-Blind, Placebo Controlled Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma.
12 years and older
Both Male & Female
Completed
The primary objective of the study is to evaluate the protective effect of fluticasone furoate/vilanterol (FF/VI) 100/25 mcg once-daily compared with fluticasone propionate (FP) 250 mcg twice-daily against exercise-induced bronchoconstriction in adolescent and adult subjects aged 12 to 50 with persistent asthma
Completed
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Study drug and placebo will be supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants will perform spirometry at every visit. Each participant will be given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) will be dispensed at each visit, if needed, as determined by the investigational center personnel.
12 Years and older
Both Male & Female
Completed
Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
The primary objective of the study is to evaluate the long-term safety of fluticasone propionate inhalation powder in 2 strengths and fluticasone propionate/salmeterol inhalation powder in 2 strengths when administered with the Teva MDPI device over 26 weeks in patients with persistent asthmaLong-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
12 Years and older
Both Male & Female
Completed
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo treatment in patients with persistent asthma as assessed by the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator).
12 years and older
Both Male and Female
Completed
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
Study drug and placebo will be supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants will perform spirometry at every visit. Each participant will be given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) will be dispensed at each visit, if needed, as determined by the investigational center personnel.
12 Years and older
Both Male & Female
Completed
AstraZeneca D5180C00007/Tezepelumab A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR)
Completed
West-Ward Columbus FLSA-P100/50-PVCL-2 A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 ug and Salmeterol Xinafoate 50 ug Inhalation Powder Compared with Advair Diskus 100/50 in Subjects with Asthm
Completed
A 12 week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of QAW039 when added to standard-of-care asthma therapy in patients with uncontrolled asthma
Completed
To Compare Therapeutic Equivalence of a Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol (manufactured by Catalent for Watson Laboratories Inc.) to Symbicort (Budesonide 80 mcg/Formoterol Fumarate Dihydrate 4.5 mcg Inhalation Aerosol, manufactured by Astra Zeneca)
Completed
Novartis CQAW039A2316 A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to standard of care asthma therapy in patients with uncontrolled asthma
Completed
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
This randomized, double-blind, double-dummy, placebo-controlled, parallel-group, 12-week study will evaluate the efficacy and safety of beclomethasone dipropionate (80 or 160 mcg/day) administered via breath-actuated inhaler (BAI) and metered-dose inhaler (MDI) in pediatric patients 4 through 11 years of age with persistent asthma, compared with placebo.
4 to 11 years
Both Male and Female
Completed
A 12-Week Study in Asthmatic Children Ages 6 to <12
The purpose is to investigate the efficacy and safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, compared with Budesonide pMDI 80 μg, 2 Actuations twice daily, in children ages 6 to <12 years with asthma during 12 weeks.
6 to 11 years
Both Male & Female
Completed
Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Age 4-11 years with Persistent Asthma
A Phase III, Randomized, Active-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Long-Term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared with Mometasone Furoate (MF, MK-0887 [SCH032088]), in Children with Persistent Asthma
Completed
Adult Patients with Atopic Dermatitis
The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately controlled with TCS.
18 Years to 75 Years
Both Male & Female
Completed
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
This is a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.
18 Years to 64 Years
Both Male & Female
Nasal Polyps for Adults
A Phase III, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with Chronic Rhinosinusitis with Nasal Polyps
Completed
Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula
Infants/children with cow's milk allergy will take part in 2 double-blinded placebo-controlled food challenges of 2 extensively hydrolyzed formulas in random order. If both food challenges are passed, subjects will be asked to consume the test formula in an at-home open challenge for 7 days.
2 Months to 4 Years
Both Male & Female
Completed
A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)
This randomized, double-blind, placebo-controlled study will evaluate efficacy and safety of subcutaneous omalizumab as an add-on therapy through 48 weeks. After completing an initial 24-week open-label treatment period with omalizumab 300 mg every 4 weeks, participants responding to omalizumab will be randomized at a 3:2 ratio (omalizumab:placebo) to either continue omalizumab or be transitioned to placebo for a further 24 weeks.
12 years to 75 years
Both Male & Female
Completed
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With Chronic Spontaneous Urticaria.
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
18 years to 75 years
Both Male & Female
Completed
Long-Term Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults. The primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).
12 Years and older
Both Male & Female
Completed
Randomized, double-blind, multi-center, parallel-group, dose-ranging, comparison of the safety and efficacy of the ZP-Zolmitriptan intracutaenous microneedle systems to placebo for the acute treatment of migraine.
Completed
Phase II HDM-SPIRE Safety and Efficacy Study
The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluate the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, quality of life and sleep quality.
18 Years to 65 Years
Both Male & Female
Active Non-Enrolling
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
